and clinical tools, as well as tracking of incidence of hospitalization admissions, morbidity, and mortality. Identification and research on potential therapeutic approaches and timing of interventions is also needed. New pharmaceutical therapies in clinical development include myostatin and the selective androgen receptor modulators (SARMs). Nonsteriodal SARMs are of particular interest, given they exhibit significant selectivity between the anabolic effects of testosterone on muscle, but with little to no evidence of androgenic effects (such as prostate stimulation in men). See also Cachexia Ageing Frailty syndrome Geriatrics Dynapenia References Further reading Sharlo K, Tyganov SA, Tomilovskaya E, Popov DV, Saveko AA, Shenkman BS. (December 2021) "Effects of Various Muscle Disuse States and Countermeasures on Muscle Molecular Signaling". International Journal of Molecular Sciences. 23(1):468. External links Aging-associated diseases Geriatrics Rehabilitation medicine Senescence